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Abstract 
Background: Prior studies examining symptoms of COVID-19 are primarily descriptive and measured among 
hospitalized individuals. Understanding symptoms of SARS-CoV-2 infection in pre-clinical, community-based 
populations may improve clinical screening, particularly during flu season. We sought to identify key symptoms and 
symptom combinations in a community-based population using robust methods. 
Methods: We pooled community-based cohorts of individuals aged 12 and older screened for SARS-CoV-2 
infection in April and June 2020 for a statewide seroprevalence study. Main outcome was SARS-CoV-2 positivity. 
We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for 
individual symptoms as well as symptom combinations. We further employed multivariable logistic regression and 
exploratory factor analysis (EFA) to examine symptoms and combinations associated with SARS-CoV-2 infection. 
Results: Among 8214 individuals screened, 368 individuals (4.5%) were RT-PCR positive for SARS-CoV-2. 
Although two-thirds of symptoms were highly specific (>90.0%), most symptoms individually possessed a PPV 
<50.0%. The individual symptoms most greatly associated with SARS-CoV-2 positivity were fever (OR=5.34, 
p<0.001), anosmia (OR=4.08, p<0.001), ageusia (OR=2.38, p=0.006), and cough (OR=2.86, p<0.001). Results from 
EFA identified two primary symptom clusters most associated with SARS-CoV-2 infection: (1) ageusia, anosmia, 
and fever; and (2) shortness of breath, cough, and chest pain. Moreover, being non-white (13.6% vs. 2.3%, 
p<0.001), Hispanic (27.9% vs. 2.5%, p<0.001), or living in an Urban area (5.4% vs. 3.8%, p<0.001) was associated 
with infection. 
Conclusions: Symptoms can help distinguish SARS-CoV-2 infection from other respiratory viruses, especially in 
community or urgent care settings where rapid testing may be limited. Symptoms should further be structured in 
clinical documentation to support identification of new cases and mitigation of disease spread by public health. 
These symptoms, derived from asymptomatic as well as mildly infected individuals, can also inform vaccine and 
therapeutic clinical trials. 
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Research in Context 
Evidence before this study 
Using multiple journal articles queried from MEDLINE as well as a Cochrane systematic review, we examined all 
studies that described symptoms known to be associated with COVID-19. We further examined the guidelines from 
WHO and CDC on the symptoms those public health authorities consider to be associated with COVID-19. Most of 
the evidence comes from China, Italy, and the United States. Collectively prior research and guidance suggests there 
are a dozen symptoms reported by individuals who tested positive for COVID-19 in multiple countries. Symptoms 
include fever, cough, fatigue, anosmia, ageusia, shortness of breath, chills, myalgias, headache, sore throat, chest 
pain, and gastrointestinal issues. The evidence is generally of low quality as it is descriptive in nature, and it is 
biased towards hospitalized patients. Most studies report the proportion of patients hospitalized or testing positive 
for infection who report one or more symptoms within 3-14 days prior to hospitalization or infection. There has been 
little validation of symptoms among hospitalized or non-hospitalized patients. Furthermore, according to a Cochrane 
review, no studies to date assess combinations of different signs and symptoms. 
Added value of this study 
This study employs multiple, rigorous methods to examine the ability of specific symptoms as well as symptom 
combinations/groups to predict laboratory-confirmed (RT-PCR) infection of SARS-CoV-2. Furthermore, the study 
is unique in its large sample drawn exclusively from community-based populations rather than hospitalized patients. 
Implication of all the available evidence 
Combining the evidence from this study with prior research suggests that anosmia and ageusia are key symptoms 
that differentiate COVID-19 from influenza-like symptoms. Clinical screening protocols for COVID-19 should look 
for these symptoms, which are not commonly asked of patients who present to urgent care or hospital with flu-like 
symptoms.  
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INTRODUCTION 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 disease, which has a range of 
manifestations from asymptomatic infection to severe pneumonia, potentially leading to intensive care utilization or 
death. Globally there have been more than 23 million cases and over 808 000 deaths as of August 24, 2020. Despite 
the advent of summer when incidence of most respiratory viruses decreases, COVID cases increased in the U.S. 
Given that the upcoming fall-winter season in the northern hemisphere typically increases influenza circulation, it is 
important to understand the common and differentiating symptoms of these two diseases. 
Symptoms of COVID-19 are similar to those of other influenza-like illnesses. Based primarily on studies of 
hospitalized individuals, the U.S. Centers for Disease Control and Prevention (CDC) recognized three principal 
symptoms for COVID-19: fever, cough, and shortness of breath.1 This list was expanded as the pandemic progressed 
to include chills, myalgias, headache, sore throat, and the loss of taste (ageusia) and/or smell (anosmia). An early 
systematic review that included 1,576 hospitalized COVID-19 patients reported that the most prevalent clinical 
symptom was fever, followed by cough, fatigue and dyspnea.2 A later review reported the main clinical symptoms to 
be fever, cough, fatigue, slight dyspnea, sore throat, headache, conjunctivitis and gastrointestinal issues.3 In a 
community-based study involving self-reported symptoms via a mobile app, 10 symptoms -- fever, persistent cough, 
fatigue, shortness of breath, diarrhea, delirium, skipped meals, abdominal pain, chest pain and hoarse voice – were 
associated with self-reported positive test results in a UK cohort.4 A Cochrane systematic review 5 identified a total 
of 27 signs and symptoms for COVID-19.  
Importantly, much of the information about prevalent COVID-19 symptoms originate from studies focused on 
limited populations who presented in a hospital setting.5 Moreover, testing guidelines in the US, and many other 
parts of the world, have prioritized symptomatic and high-risk individuals, which further biases available data on 
symptomology towards those with more severe disease. Most studies further focus exclusively on SARS-CoV-2 
positive patients and thus lack an uninfected control group which might also exhibit some level of baseline 
symptoms. In Menni et al.,4 app users self-reported test results limiting reliability of findings in an uncontrolled 
study. The Cochrane review suggests the existing evidence on symptoms is “highly variable,” and no studies to date 
assessed combinations of different signs and symptoms.5 In summary, there is much that can still be learned about 
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the symptomatology of SARS-CoV-2 infection, especially among community-based individuals who may not 
require or have not yet presented for clinical care. 
We sought to examine the symptoms reported by populations of community-based individuals tested for SARS-
CoV-2 in the context of a statewide prevalence study. We examine patterns and groups of symptoms, and we 
compare individuals who tested positive for active viral infection, using RT-PCR, to those who screened negative.  
We also examine symptom differences by age, sex, race, ethnicity, and rurality. By better characterizing COVID-19 
symptoms, especially among those that may have milder disease, we sought to better identify those symptoms and 
symptom combinations that are more likely to represent SARS-CoV-2 infection. In addition, understanding the 
symptomology of community-based infections has the potential to inform the selection of end points for 
consideration in clinical trials focused on vaccine and therapeutic effectiveness. 
METHODS 
Study Participants and Recruitment 
Data derived from two waves of testing in Indiana, conducted in partnership with the state health department, were 
analyzed for this study. Each wave included groups that were either randomly selected or that sought testing in 
open-testing sites throughout the state. Wave 1 of testing, described elsewhere,6 occurred at the end of April 2020.  
Wave 2 occurred in the beginning of June 2020. The random sample for each wave was selected from individual 
state tax records of filers and dependents. In addition, because underrepresented minority groups are more seriously 
impacted by COVID-19, both waves also conducted targeted nonrandom testing, in conjunction with religious and 
civic leaders, in select African American and Hispanic communities. In all cases, inclusion criteria were Indiana 
residency and being 12 years of age or older. Individuals from both random and nonrandom samples were tested 
regardless of symptoms, prior testing history, or medical history. Testing was available with no out-of-pocket costs 
to participants.   
Recruitment was aided by public announcements by the Governor, the media, and minority community leaders. 
State agencies, including the Indiana Minority Health Coalition, reached out to minority communities to encourage 
participation. The testing was a component of the state’s overall effort to expand testing capacity and surveillance 
for COVID-19. 
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COVID-19 Testing and Specimen Collection 
Using Dacron swabs and standard techniques, trained personnel collected nasopharyngeal swabs for RT-PCR 
analysis. Nasopharyngeal swabs were transferred to the laboratories of Eli Lilly and Company (Lilly Clinical 
Diagnostics Lab SARS-CoV-2 test based on the CDC primary set) or Indiana University Health (Luminexon 
NxTAG CoV Extended Panel or Roche cobas SARS-CoV-2 test) for RT-PCR testing. All laboratories were located 
in Indianapolis, IN. Test results were reported to participants via a secure website within 1 to 4 days. 
Data Collection 
Upon arrival to a testing site, each participant was asked to complete a research intake form that included questions 
about symptoms, health status, and demographics. Using a standardized checklist, participants were asked to 
indicate presence of symptoms within the past two weeks (14 days). The checklist represented a composite of 
symptoms reported by either the WHO or the CDC to be associated with COVID-191 and expanded to include 
additional symptoms reported in the literature.7,8 Participants were requested to identify all symptoms present, and 
those who did not indicate any symptoms were categorized as asymptomatic. 
Statistical Analysis 
Because the target populations, identification, and recruitment processes were similar between the two waves, all 
participants from both waves were pooled for analysis. Descriptive statistics were calculated for all individuals who 
participated in testing for SARS-CoV-2, stratified by the recruitment method (e.g., random, or nonrandom). Chi-
square tests were used to compare various characteristics between the two groups as well as characteristics of 
individuals testing positive for SARS-CoV-2 versus those testing negative. 
Using all available data, we first examined the sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) of each symptom reported by participants. Because specific combinations of symptoms 
might be useful in screening patients who present to a clinic or hospital, we further explored various symptom 
combinations. First, we examined the sensitivity, specificity, PPV and NPV of symptom pairs and triplets. All such 
symptom permutations were examined. To further explore symptom combinations, we employed exploratory factor 
analysis (EFA) to create symptom groups using positive RT-PCR status as the gold standard for identification of 
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SARS-CoV-2 infection. Factor analysis is a recommended multivariate method for exploring symptoms when 
symptoms are commonly grouped together in a given etiology.9 
Furthermore, we developed a logistic regression model to examine the relationship between the presence of 
individual symptoms and positive RT-PCR status, controlling for participant demographics and sample recruitment 
method. The logistic regression model computes the probability of positive RT-PCR status ranging from 0 to 1. We 
then generated a Receiver Operating Characteristic (ROC) curve associated with the model by varying the cut-off 
probability across the range of observed values using the pROC package in R. These are plots of the true-positive 
(sensitivity) versus the false-positive rate (1 – specificity) of a test, over all possible cutoff points.10 We also 
calculated the area under the ROC curve (AUC) as a global measure of the accuracy of the model to predict SARS 
CoV-2 positivity.  
All analyses were performed using R (version 3.6.3). This study was determined to be exempt by the Institutional 
Review Board (IRB) at Indiana University under the public health surveillance exception. 
Role of the Funding Source 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of 
the paper. The corresponding author had full access to all the data in the study and had final responsibility for the 
decision to submit for publication. 
RESULTS 
We screened a total of 8214 individuals for SARS-CoV-2 including 6326 (77.0%) individuals who were randomly 
selected and 1888 (23.0%) who were recruited for nonrandom testing in partnership with racial and ethnic minority 
community leaders. A total of 368 individuals (4.5%) were RT-PCR positive for SARS-CoV-2. The characteristics 
of tested participants are summarized in Table 1. Randomly selected and nonrandom participants were significantly 
(p<0.001) different on all characteristics. The nonrandom group included more males (45% vs. 41%, p<0.001), non-
whites (57.2% vs. 8.5%, p<0.001), Hispanics (27% vs. 2.3%, p<0.001), and urban (80.6% vs. 65%, p<0.001) 
residents. Males and females tested positive in similar proportions (4.6% vs. 4.4%, p=0.707). Non-whites (13.6% vs. 
2.3%, p<0.001), Hispanics (27.9% vs. 2.5%, p<0.001), and individuals living in Urban areas (5.4% vs. 3.8%, 
p<0.001) had higher rates of positivity. 
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<Insert Table 1 approximately here> 
Symptoms experienced by individuals who tested positive or negative and the sensitivity, specificity, PPV, and NPV 
for each individual symptom with respect to predicting RT-PCR positivity are summarized in Table 2. Also 
presented are combinations of symptoms with a PPV ≥60.0%. Although two-thirds of the symptoms were highly 
specific for COVID-19 (>90.0%), most symptoms individually possessed a PPV of <50.0%. The three symptoms 
with the largest individual PPVs were anosmia (52.5%), ageusia (51.0%), and fever (47.6%). When fever was paired 
with anosmia or ageusia, with or without the presence of a third symptom, the PPV increased to >70%. However, 
sensitivity for all individual symptoms and symptom combinations was low (<50.0%). 
<Insert Table 2 approximately here> 
Symptom Groups 
The principal symptom groups identified through EFA are summarized in Figure 1. Five principal symptom groups 
emerged, all of which have face validity. The first symptom group (Factor 1) consists of ageusia (r=0.92), anosmia 
(r=0.90), fever (r=0.63). The second symptom group (Factor 2) consists of shortness of breath (r=0.83), cough 
(r=0.49), and chest pain (r=0.64). The third symptom group (Factor 3) consists of fatigue (r=0.73) and myalgias 
(r=0.71). The fourth symptom group (Factor 4) consists of vomiting (r=0.90) and diarrhea (r=0.55). The final 
symptom group (Factor 5) consists of runny nose (r=0.80) and sore throat (r=0.44). The cumulative variance 
explained by all symptom groups was 70%, with the first two groups (Factors 1 and 2) explaining 49% of the 
variance.  
<Insert Figure 1 approximately here> 
Predicting COVID-19 Positivity based on Symptoms and Demographics 
The results of the logistic regression model that examined how individual symptoms were associated with RT-PCR 
positivity are presented in Table 3. When controlling for demographics as well as testing group (e.g., random vs. 
nonrandom sample) and other symptoms, individual symptoms most strongly associated with high odds of RT-PCR 
SARS-CoV-2 positivity were fever (OR=5.34, p<0.001), anosmia (OR=4.08, p<0.001), ageusia (OR=2.38, 
p=0.006), and cough (OR=2.86, p<0.001). The ROC curve generated by a test based on this cluster of symptoms is 
presented in Figure 2. The AUC for the diagnostic index generated by the model which included this symptom 
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cluster was 0.909. Individuals from the nonrandom sample were more likely than randomly selected participants to 
test positive (OR=9.34, p<0.001). Hispanic participants were more likely (OR=2.44, p<0.001) to test positive than 
non-Hispanic participants. Older participants, age ≥60 years, were less likely (OR=0.43, p<0.001) to test positive 
compared to participants under 40 years of age. 
<Insert Table 3 approximately here> 
<Insert Figure 2 approximately here> 
DISCUSSION 
In this study of populations screened for COVID-19, we observed a wide constellation of symptoms present among 
those testing positive for active infection. Many symptoms commonly reported by infected participants (e.g., cough, 
fatigue, headache, myalgias) were similar to those identified by the CDC1 and those reported in prior studies.3,7,8,11-13 
However, unlike prior studies, we also captured symptoms from those testing negative, enabling the examination of 
the sensitivity, specificity, PPV and NPV of individual symptoms and symptom combinations. 
Our findings provide robust evidence to the growing body of studies that identify anosmia and ageusia as important 
symptoms of SARS-CoV-2 infection.11,14,15 These symptoms, especially in association with fever, are highly 
predictive of positive status and should trigger use of personal protective equipment (PPE), if universal PPE is not 
already being utilized, and prompt testing for COVID-19. Furthermore, particularly as influenza season arrives, it is 
important that health care providers specifically ask questions about loss of taste and smell in addition to traditional 
questions asked for assessing respiratory tract illness. Moreover, documenting these symptoms can aid public health 
officials in distinguishing COVID-19 from influenza within syndromic surveillance systems16 during flu season. 
Currently syndromes recommended by CDC and others overlap with influenza-like illness, and few electronic health 
record (EHR) systems capture information about loss of taste or smell. 
We further observed a high rate of asymptomatic or pre-symptomatic individuals with 44.2% of the randomly 
selected participants and 20.2% of the nonrandom participants reporting a lack of related symptoms within two 
weeks of their positive RT-PCR test.6 A high rate of asymptomatic infection likely influenced the overall low PPV 
and sensitivity for individual symptoms and symptom combinations. The high proportion of asymptomatic cases 
complicates identification, control, and containment of new SARS-CoV-2 infections by public health authorities. 
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Virtual health care screening as well as chatbots and mobile applications17,18 are unlikely to refer asymptomatic 
individuals for testing. Without sufficient capacity for rapid, inexpensive testing, screening efforts may be hampered 
and accurate measurement of incidence and prevalence will be challenging. 
As observed in other studies that analyzed cases,19,20 we found higher infection rates among Hispanic and non-white 
populations. These results were largely influenced by individuals involved in the nonrandom samples, who 
presented to community-based testing sites. Higher burden of disease among people of color have been widely 
reported and may stem from systemic inequities in economic, physical, and emotional health (e.g., social 
determinants).21 Targeted efforts to screen and test minority and other underserved populations, in coordination with 
public health and community-based organizations, are needed to adequately identify and reduce COVID-19 
disparities.   
Limitations 
We acknowledge several limitations. First, the two testing waves occurred as influenza season waned, which may 
decrease the presence of influenza-like-illness symptoms among those testing negative for COVID-19. Second, the 
association between age and RT-PCR positivity, e.g., older participants (60+ years) were less likely to test positive, 
may be driven by non-response to the sampling by these groups, as elderly and frail individuals may not have been 
as likely to participate in our studies as they were either tested in a nursing home (a population excluded from our 
sample) or were unlikely to present to a testing site. It is likely the differences observed in positivity among non-
white and Hispanic populations are due to their self-selecting into testing at the nonrandom sites. They might have 
been more symptomatic and therefore motivated to seek testing as opposed to the randomized individuals. Finally, 
although the population was representative of Indiana, the cohort might not represent other states or the nation. 
Despite these limitations, the study possessed significant strengths. The cohort was large and diverse, and it was 
drawn from a statewide population. Second, the symptoms examined were broad and included the most complete list 
based on available evidence. Finally, the robust methods yielded a strong model with face validity. 
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CONCLUSION 
This study finds that key symptoms for identifying active SARS-CoV-2 infection are anosmia and ageusia, 
especially in association with fever. Cough, especially when present along with shortness of breath and chest pain, is 
also an important symptom when diagnosing COVID-19. When laboratory testing is not accessible, these symptoms 
may help guide distinguishing COVID-19 from influenza-like illness. These symptoms should be used for screening 
and incorporated into clinical documentation to support public health identification of new cases and mitigation of 
disease spread. 
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Figures 
Figure 1. Results from the exploratory factor analysis of symptom clusters.  
(caption) The figure summarizes the principal symptoms loading on each factor. The proportions represent 
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Table 1 – Characteristics of Indiana residents who were tested for SARS-CoV-2 infection in late April and 
early June 2020, includes are individuals randomly selected for testing along with nonrandom samples 



























Overall Population Totals 8214 6326 1888   368  
       
Female 4565 (55.6%) 3451 (54.6%) 1114 (59.0%) <0.001 201 (4.4%) 0.71 
Male 3647 (44.4%) 2873 (45.4%) 774 (41.0%)  167 (4.6%) 
       
White 6599 (80.3%) 5791 (91.5%) 808 (42.8%) <0.001 149 (2.3%) <0.001 
Non-white 1615 (19.7%) 535 (8.5%) 1080 (57.2%)  219 (13.6%) 
       
Hispanic 653 (7.9%) 144 (2.3%) 509 (27.0%) <0.001 182 (27.9%) <0.001 
Non-Hispanic 7561 (92.1%) 6182 (97.7%) 1379 (73.0%)  186 (2.5%) 
       
Urbanc 5631 (68.6%) 4109 (65.0%) 1522 (80.6%) <0.001 303 (5.4%) <0.001 
Rural/Mixed 1598 (19.5%) 1500 (23.7%) 98 (5.2%)  27 (1.7%) 
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aComparison of Randomly Selected individuals to nonrandom community testing 
bComparison of Individuals Testing Positive to those Testing Negative 
cBased upon Purdue Rural Indiana Classification System 
 
  
Rural 980 (11.9%) 717 (11.3%) 263 (13.9%)  37 (3.8%) 
       
Age: <40 2379 (29.0%) 1747 (27.6%) 632 (33.5%) <0.001 167 (7.0%) <0.001 
Age: 40-59 3036 (37.0%) 2308 (36.5%) 728 (38.6%)  155 (5.1%) 
Age: 60+ 2799 (34.1%) 2271 (35.9%) 528 (28.0%)  46 (1.6%) 
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Table 2 – Self reported symptoms by participants undergoing SARS-CoV-2 testing in a statewide prevalence 
study. All individual symptoms and lack of symptoms (asymptomatic) included as well as combinations of 
symptoms with a positive predictive value >60%. 
Symptoms reported in the 




















Overall Population Totals 368 (4.6) 7650 (95.4)     
Asymptomatic (no reported 
symptoms) 
91 (24.7) 4681 (61.2) 24.7% 38.8% 1.9% 91.5% 
Individual Symptoms       
Loss of Smell (anosmia) 94 (25.5) 85 (1.1) 25.5% 98.9% 52.5% 96.5% 
Loss of Taste (ageusia) 105 (28.5) 101 (1.3) 28.5% 98.7% 51.0% 96.6% 
Fever 129 (35.1) 142 (1.9) 35.1% 98.1% 47.6% 96.9% 
Chills 81 (22) 197 (2.6) 22.0% 97.4% 29.1% 96.3% 
Chest Pain 65 (17.7) 255 (3.4) 17.7% 96.6% 20.3% 96.0% 
Vomiting 12 (3.3) 51 (0.7) 3.3% 99.3% 19.0% 95.5% 
Muscle Ache (myalgia) 117 (31.8) 564 (7.4) 31.8% 92.6% 17.2% 96.6% 
Cough 175 (47.6) 969 (12.7) 47.6% 87.3% 15.3% 97.2% 
Shortness of Breath 64 (17.4) 438 (5.8) 17.4% 94.2% 12.7% 95.9% 
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Symptoms reported in the 




















Sore Throat 90 (24.5) 618 (8.1) 24.5% 91.9% 12.7% 96.2% 
Diarrhea 59 (16) 479 (6.3) 16.0% 93.7% 11.0% 95.8% 
Fatigue 127 (34.5) 1063 (14) 34.5% 86.0% 10.7% 96.4% 
Headache 144 (39.1) 1376 (18.1) 39.1% 81.9% 9.5% 96.5% 
Runny Nose 90 (24.5) 1116 (14.7) 24.5% 85.3% 7.5% 95.9% 
Symptom Combinations       
Fever & Loss of Taste 
(ageusia) 
63 (17.1) 24 (0.3) 17.1% 99.7% 72.4% 96.1% 
Fever & Loss of Smell 
(anosmia) 
53 (14.4) 22 (0.3) 14.4% 99.7% 70.7% 96.0% 
Loss of Taste & Vomiting 8 (2.2) 4 (0.1) 2.2% 99.9% 66.7% 95.5% 
Cough & Fever & Loss of 
Taste (ageusia) 
49 (13.3) 13 (0.2) 13.3% 99.8% 79.0% 96.0% 
Cough & Fever & Loss of 
Smell (anosmia) 
41 (11.1) 13 (0.2) 11.1% 99.8% 75.9% 95.9% 
Fever & Loss of Smell 37 (10.1) 13 (0.2) 10.1% 99.8% 74.0% 95.8% 
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Symptoms reported in the 




















(anosmia) & Muscle Ache 
(myalgia) 
Fever & Loss of Taste 
(ageusia) & Muscle Ache 
(myalgia) 
46 (12.5) 18 (0.2) 12.5% 99.8% 71.9% 95.9% 
Fever & Loss of Smell 
(anosmia) & Loss of Taste 
(ageusia) 
45 (12.2) 18 (0.2) 12.2% 99.8% 71.4% 95.9% 
Fever & Headache & Loss of 
Smell (anosmia) 
42 (11.4) 17 (0.2) 11.4% 99.8% 71.2% 95.9% 
Fatigue & Fever & Loss of 
Smell (anosmia) 
36 (9.8) 15 (0.2) 9.8% 99.8% 70.6% 95.8% 
Chills & Fever & Loss of 
Smell (anosmia) 
26 (7.1) 11 (0.1) 7.1% 99.9% 70.3% 95.7% 
Diarrhea & Fever & Loss of 
Taste (ageusia) 
23 (6.2) 10 (0.1) 6.2% 99.9% 69.7% 95.7% 
Chills & Fever & Loss of 36 (9.8) 16 (0.2) 9.8% 99.8% 69.2% 95.8% 
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Symptoms reported in the 





















Fever & Headache & Loss of 
Taste (ageusia) 
47 (12.8) 21 (0.3) 12.8% 99.7% 69.1% 95.9% 
Fatigue & Fever & Loss of 
Taste (ageusia) 
42 (11.4) 19 (0.2) 11.4% 99.8% 68.9% 95.9% 
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Table 3 – Logistic regression model to predict SARS-CoV-2 RT-PCR positivity using participant reported 
symptoms and demographics. 
Symptom AOR1 95% CI1 p-value 
Fever 5.34 3.51, 8.12 <0.001 
Loss of Smell 
(Anosmia) 
4.08 2.14, 7.74 <0.001 
Loss of Taste (Ageusia) 2.38 1.28, 4.45 0.01 
Cough 2.86 2.06, 3.97 <0.001 
Shortness of Breath 0.61 0.36, 1.00 0.05 
Chest Pain 1.00 0.60, 1.64 >0.999 
Muscle Ache (Myalgia) 1.07 0.70, 1.61 0.75 
Fatigue 1.25 0.84, 1.82 0.27 
Headache 0.75 0.52, 1.07 0.12 
Diarrhea 1.00 0.62, 1.58 0.99 
Vomiting 1.35 0.47, 3.60 0.56 
Sore Throat 0.80 0.53, 1.18 0.27 
Runny Nose 1.14 0.79, 1.63 0.46 
Demographics    
Age: <40 — —  
Age: 40-59 0.88 0.66, 1.18 0.41 
Age: 60+ 0.43 0.28, 0.63 <0.001 
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Male 1.19 0.91, 1.56 0.21 
Race    
White — —  
Black or African 
American 
0.80 0.49, 1.26 0.34 
Other 1.68 1.17, 2.41 0.01 
Hispanic 2.44 1.68, 3.54 <0.001 
Geography    
Urban — —  
Rural 1.53 0.97, 2.37 0.06 
Rural/Mixed 1.30 0.79, 2.06 0.29 
Participation    
Random Sample — —  
Nonrandom Sample 9.35 6.59, 13.4 <0.001 
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